SSRI-related adverse events costly?

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.337, 2001-01, pp. : 10-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Routine screening for prevention of neonatal kernicterus too costly?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 467, 2004-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

NSAID-Related Psychiatric Adverse Events: Who is at Risk?

By Graziano Onder Francesca Pellicciotti Giovanni Gambassi Roberto Bernabei

Drugs, Vol. 64, Iss. 23, 2004-01 ,pp. : 2619-2627

Adis International

Access to resources Recommend Favorite

Quantifying Adverse Drug Events: Are Systematic Reviews the Answer?

By Mahyar Etminan Bruce Carleton Paula A. Rochon

Drug Safety, Vol. 27, Iss. 11, 2004-01 ,pp. : 757-761

Adis International

Access to resources Recommend Favorite

Alemtuzumab: a costly alternative in CLL?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 605, 2010-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Optimal treatment for PMDD: SSRI or oral contraceptive?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 598, 2010-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite